Novel Trace Amine Receptor Associated With Significant Antipsychotic Effects in Schizophrenia

News
1

Novel trace amine associated receptor-1 agonist SEP-363856 has significant antipsychotic effects in patients with schizophrenia, according to results of a study presented at Psych Congress 2019, held October 3 to 6 in San Diego, California. There were no notable differences between treatment with SEP-363856 and placebo in terms of safety and tolerability.

https://www.psychiatryadvisor.com/home/conference-highlights/us-psych-congress-2019/novel-trace-amine-receptor-associated-with-significant-antipsychotic-effects-in-schizophrenia/

5 Likes
2

Exciting stuff. This is THE med I am hoping passes all clinical trials. Come on!

2 Likes
3

Oh, just realised this is the Phase 2 trial already reported. Oh well - Iā€™m still psyched for this.

4

There were no notable differences between treatment with SEP-363856 and placebo in terms of safety and tolerability.

Sounds good.

1 Like